Document is current

Article History

Received: 7 September 2023

Accepted: 31 July 2024

First Online: 7 August 2024

Declarations

:

: This research was conducted in accordance with the Declaration of Helsinki, and the study protocol was reviewed by the Mayo Clinic Institutional Review Board (IRB 1815–04).

: The authors confirms that the work described has not been published before (except in the form of an abstract); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, and that its publication has been approved by the responsible authorities at the institution where the work is carried out. The authors warrants that their contribution is original and that they have full power to make this consent.

: C. O’Sullivan – Dr. O’Sullivan has research funding to Mayo Clinic from Lilly, Seagen Inc., Bavarian Nordic, Minnemarita Therapeutics, nFerence, AstraZeneca and Biovica. N. Larson—None R. Vierkant—None Mary Lou Smith – Consulting/advisory boards with Bayer, Eisai, Novartis, Pfizer, and Rising Tide. Grant funding to institution from Genentech, Foundation Medicine, Novartis, Seagen, Eli Lilly, Exact Sciences, Daiichi, ECOG-ACRIN Medical Research Foundation, Pfizer, Prelude DX, International Association for Study of Lung Cancer, Conquer Cancer Foundation, and Cholangiocarcinoma Foundation. Serves as Co-Chair of Cancer Research Advocate Committee and Member of Breast Core Committee, ECOG ACRIN Research Group. Was a member to the following: Breast Cancer Treatment Guidelines Committee, National Comprehensive Cancer Network (NCCN) External Advisory Board, University of Wisconsin Comprehensive Cancer Center Board of Directors, National Accreditation Program for Breast Centers Board of Directors, Gateway for Cancer Research NCI BOLD Task Force Mayo Clinic Breast SPORE Steering Committee, ASCO TAPUR Study Stakeholder Advisory Board, COMET study Advisory Board, PRO-TECT study Advisory Committee, NCI-NCORP Breast Cancer Guidelines Advisory Group, American Society of Clinical Oncology (ASCO) EVOLV Study NCI Tolerability Consortium Women's Advisory Board, TMIST study Cynthia Chauhan—None Fergus Couch—None Janet E. Olson – Research support: Grail, Inc. Research grant: Exact Sciences, Exact-001. Charles Loprinzi—PledPharma, Disarm Therapeutics, Asahi Kasei/Veloxis,Metys Pharmaceuticals, OnQuality, Mitsubishi Tanabe, NKMax, HengRui, Osmol Therapeutics, Inc., Grunenthal, Bexion, Metys pharmaceuticals, Hengrui Pharmaceuticals, Neuropathix, Dernsli Theraapeutics, Galendia, Genentcch, Nevro, and Toray. Kathryn J. Ruddy – None.N. Larson—None.R. Vierkant—None.Mary Lou Smith – Consulting/advisory boards with Bayer, Eisai, Novartis, Pfizer, and Rising Tide. Grant funding to institution from Genentech, Foundation Medicine, Novartis, Seagen, Eli Lilly, Exact Sciences, Daiichi, ECOG-ACRIN Medical Research Foundation, Pfizer, Prelude DX, International Association for Study of Lung Cancer, Conquer Cancer Foundation, and Cholangiocarcinoma Foundation. Serves as Co-Chair of Cancer Research Advocate Committee and Member of Breast Core Committee, ECOG ACRIN Research Group.Was a member to the following:Breast Cancer Treatment Guidelines Committee, National Comprehensive Cancer Network (NCCN).External Advisory Board, University of Wisconsin Comprehensive Cancer Center.Board of Directors, National Accreditation Program for Breast Centers.Board of Directors, Gateway for Cancer Research.NCI BOLD Task Force.Mayo Clinic Breast SPORE.Steering Committee, ASCO TAPUR Study.Stakeholder Advisory Board, COMET study.Advisory Board, PRO-TECT study.Advisory Committee, NCI-NCORP.Breast Cancer Guidelines Advisory Group, American Society of Clinical Oncology (ASCO).EVOLV Study.NCI Tolerability Consortium.Women’s Advisory Board, TMIST study.Cynthia Chauhan—None.Fergus Couch—None.Janet E. Olson – Research support: Grail, Inc. Research grant: Exact Sciences, Exact-001.Kathryn J. Ruddy – None.Consent to Participate: Informed consent was obtained from all participants prior to enrollment to the registry.